# Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

> **NCT04555837** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Alisertib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04555837
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-04-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555837, "Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04555837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*